An ownership shake-up could be on the cards at TPG Capital’s Novotech.
While a full sale to a rival private equity firm is looking less likely after Bain Capital went cold on price and New York’s Kohlberg & Company faded as a buyer, Street Talk understands TPG is weighing up a bunch of new options for its $4 billion clinical research group.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
